Objective To observe the curative effects of Guillain-Barre Syndrome(GBS) treated with large dose of immunoglobulin.Methods 34 patients with acute GBS were randomly divided into intravenous immunoglobulin(IVIG) group and control group(17 cases in each group).The patients in IVIG group were treated with intravenous injection of human immunoglobulin 0.4 g/(kg?d) for five days,while the other treatment of two groups was similar.The curative effects was evaluated at 21 days after therapy.Results The cure-rate(52.9%) and total effective rate(100%) in IVIG group were signifcantly higher than those in control group(11.8% and 76.5%)(all P

Objective To compare sleep electroencephalogram-modulated repetitive transcranial magnetic stimulation (SEM-rTMS) with routine repetitive transcranial magnetic stimulation (R-rTMS) in the treatment of primary insomnia. Methods One hundred and twenty six patients with insomnia were divided randomly into a SEM-rTMS group (44 cases) , a R-rTMS group (42 cases) and a sham rTMS group (40 cases). Each case was treated with rTMS for 30 min once a day for 10 d under double blinding of the patient and therapist. The clinical effect was observed along with Krakow sleep scores, electroencephalograms and blood pressure before and after a 10-day course of therapy and 30 days later. Results During rTMS treatment, some patients reported feeling sleepy, and this was confirmed by their EEGs at the time. After the entire course of therapy, 80% of the SEM-rTMS group and 45% of the R-rTMS group showed improvements, a significant difference. At the 30th day after therapy, the effect in the SEM-rTMS group was still significantly better than in the R-rTMS group. There were no obvious side effects in any group throughout the whole observation period. Conclusions SEM-rTMS is more effective and more reliable than R-rTMS. SEM-rTMS is safe to use with primary insomnia patients.

OBJECTIVE:To investigate the effects of TanshinoneⅡA sodium sulfonate injection on levels of P-selectin,glial fi-brillary acidic protein (GFAP),vascular endothelial growth factor (VEGF) and neurological function in patients with acute cere-bral infarction. METHODS:A total of 114 patients with acute cerebral infarction selected from Lianyungang First People's Hospi-tal during Apr. 2013-Apr. 2016 were divided into control group and observation group according to random number table,with 57 cases in each group. Control group was given routine treatment. Observation group was additionally given Tanshinone ⅡA sodium sulfonate injection 40 mg 0.9％ sodium chlonride injection 250 mL,ivgtt,qd. A treatment course lasted for 7 d,and both received 2 courses of treatment. NIHSS scores,the levels of serum P-selectin,GFAP and VEGF were compared between 2 groups before treatment and after 7,14 d of treatment. The occurrence of ADR was also compared. RESULTS:Before treatment,there was no statistical significance in above indexes between 2 groups(P>0.05). Compared to before treatment,NIHSS score,the levels of se-rum P-selectin and GFAP in 2 groups were decreased significantly after 7,14 d of treatment,while the serum level of VEGF was increased significantly. These indexes of 2 groups after 14 d of treatment were significantly better than 7 d of treatment,except for NIHSS score. Above indexes of observation group was significantly better than those of control group during corresponding period, with statistical significance (P<0.05). No obvious ADR was found in 2 groups. CONCLUSIONS:For acute cerebral infarction, Tanshinone ⅡA sodium sulfonate injection can significantly reduce the levels of serum P-selectin and GFAP,improve VEGF level and promote the recovery of neurological damage with good safety.

Objective:To investigate the predictive value of stress hyperglycemia for the functional outcomes in patients with acute ischemic stroke (AIS).Methods:Patients with AIS admitted to the Affiliated Hospital of Lianyungang, Xuzhou Medical University from September 1, 2019 to December 31, 2020 were enrolled prospectively. The glucose to glycated hemoglobin ratio (GAR) was used to express stress hyperglycemia. The functional outcome was evaluated by the modified Rankin Scale at 3 month after discharge, 0-2 was defined as a good outcome and >2 as a poor outcome. Multivariate logistic regression analysis was used to determine the independent related factors of functional outcome. Receiver operating characteristic (ROC) curve was used to evaluate the predictive value of GAR for poor functional outcome. Results:A total of 1 286 patients with AIS were included. Their median age was 67 years old, and 762 were males (59.3%). The median baseline National Institutes of Health Stroke Scale (NIHSS) score was 2. The median fasting blood glucose level was 5.48 mmol/L, the median glycosylated hemoglobin was 6.00%, and the median GAR was 0.92. Eight hundred and twelve patients (63.1%) had good outcomes and 474 (36.9%) had poor outcomes. The GAR in the good outcome group was significantly lower than that in the poor outcome group (0.86 vs. 1.03; P<0.001). All patients were divided into 4 groups (GAR1, GAR2, GAR3, and GAR4) according to the GAR quartile from low to high. Multivariate logistic regression analysis showed that after adjusting for relevant confounding factors, GAR4 (taking the GAR1 as a reference, odds ratio [ OR] 8.896, 95% confidence interval [ CI] 5.775-13.702; P<0.001), age ( OR 1.041, 95% CI 1.027-1.055; P<0.001) and baseline NIHSS score classification ( OR 25.898, 95% CI 14.221-47.163; P<0.001) were closely associated with the poor outcomes at 3 months. Further subgroup analysis showed that the higher level of GAR was significantly and independently correlated with the poor functional outcome, regardless of whether the patients had diabetes or not. The ROC curve analysis showed that the area under the curve of GAR predicting poor outcome at 3 months was 0.705 (95% CI 0.675-0.735; P<0.001), and the predictive value was significantly higher than that of glycosylated hemoglobin and fasting blood glucose. When the cut-off value of GAR was 0.97, the Yoden index was the largest, which was 0.370. The sensitivity and specificity of its predicting the poor outcome at 3 months were 61.6% and 75.4%. Conclusion:Whether or not diabetes is present, GAR is an independent predictor of the poor outcomes in patients with AIS.